GammaDelta Therapeutics announced as winner of the 2018 Outstanding Achievement Award at the OBN Annual Awards Ceremony.

Dan Kemp, PhD

Board Member

Dan Kemp is a Senior Director at Takeda Pharmaceuticals, leading R&D collaboration deals and transactions primarily in the oncology space. Previously, Dr. Kemp was Senior VP at Beryllium, and responsible for directing drug discovery partnerships. From 2008 to 2013, Dan ran programmes from Target Validation through clinical proof of concept at Merck Research Laboratories, and between 2003-2008 led a team at Novartis Institutes for BioMedical Research developing innovative concepts for metabolic diseases.

Dr. Kemp has authored over 30 papers or book chapters, of which he is first, last, or corresponding author on over 20, and of which 24 are original research contributions. He received a BSc in 1996 and a PhD in 2000 from the University of Kent at Canterbury, and was awarded an HHMI Research Fellowship at Harvard Medical School.